Author’s response to reviews

Title: Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304

Authors:

Kazuhiro Tanaka (ktanaka@oita-u.ac.jp)
Junki Mizusawa (jmizusaw@ncc.go.jp)
Norifumi Naka (naka-no@mc.pref.osaka.jp)
Akira Kawai (akawai@ncc.go.jp)
Hirohisa Katagiri (h.katagiri@scchr.jp)
Toru Hiruma (hirumat@kcch.jp)
Yoshihiro Matsumoto (ymatsu@ortho.med.kyushu-u.ac.jp)
Hiroyuki Tsuchiya (tsuchi@med.kanazawa-u.ac.jp)
Robert Nakayama (robert.a2@keio.jp)
Hiroshi Hatano (orthatano@niigata-cc.jp)
Makoto Emori (emrmkt@yahoo.co.jp)
Munenori Watanuki (mwata@ortho.med.tohoku.ac.jp)
Yukihiro Yoshida (yoshida.yukihiro@nihon-u.ac.jp)
Takeshi Okamoto (okaken@kuhp.kyoto-u.ac.jp)
Satoshi Abe (satoshi@med.teikyo-u.ac.jp)
Kunihiro Asanuma (kas numeral@gmail.com)
Ryohei Yokoyama (ryokoya@nk-cc.go.jp)
Hiroaki Hiraga (hhiraga@nho-hcc.jp)
Tsukasa Yonemoto (tyonemot@chiba-cc.jp)
Dear Dr. Gummlich,

Thank you very much for your e-mail dated August 28, 2019 with regard to our manuscript (BCAN-D-19-01638R1) together with the comments from the reviewer and Assistant Editor. It is our pleasure to resubmit a re-revised version of our manuscript for publication as an original study in BMC Cancer.

We have incorporated the suggested changes into the manuscript to the best of our ability. The manuscript has certainly benefited from these suggestions. The following pages include the responses to each reviewer’s comments.

We appreciate your time and consideration and hope that our responses are satisfactory. Thank you again for thoroughly reviewing our manuscript.

Please let us know if any additional information is required. We look forward to your decision.
Sincerely,

Kazuhiro Tanaka
Department of Orthopaedic Surgery, Oita University
Idaigaoka 1-1, Hasama, Yufu City, Oita 879-5593, Japan
Phone: +81-97-586-5872; Fax: +81-97-586-6647
E-mail: ktanaka@oita-u.ac.jp

Response to the comments:

Dr. Scott Michael Schuetze (Reviewer 2)

1. The authors have addressed the comments/suggestions provided by the reviewers. Minor editorial assistance is needed to help with English grammar.

Thank you for your comment. According to your suggestion, we asked a professional English editing service for checking throughout the manuscript. We added the acknowledgement about the copyediting (Page 26, Line 390).

Associate Editor

1. Copy Edit

-- Your manuscript needs to be copyedited. We recommend that you ask a native English speaking colleague to help you copyedit the paper.

Thank you for your comment. According to your suggestion, we asked a professional English editing service for checking throughout the manuscript. We added the acknowledgement about the copyediting (Page 26, Line 390).

2. Ethics

Thank you for stating 'was also approved by the Institutional Review Boards of each of the 27 participating institutions'.
-- Please include the individual names of each ethics committee that approval was obtained from. This may be listed as an additional file and cited under 'ethics approval and consent to participate'.

Thank you for your comment. According to your suggestion, we included the individual names of each ethics committee that approval was obtained from in Additional File1: Table S1, and cited under 'ethics approval and consent to participate'. (Page 24, Line 361).

3. Abstract

Please include a statement under 'acknowledgements' to clarify that your abstract has been previously presented at XXX conference [http://abstracts.asco.org/239/AbstView_239_257101.html]. Please also ensure the link is cited and included under your references.

Thank you for your comment. According to your suggestion, we included the statement under 'acknowledgements' to clarify that the abstract has been previously presented at 2019 ASCO meeting (Page 26 Line 388), and cited under the references (Page 32, Line 467).

4. Author Contributions

-- Please consider the list of authors as it currently stands with reference to our guidelines regarding qualification for authorship. Currently, the contributions of authors NN, AK, HK, TH, YM, HT, RN, HH, TY, TM, KA, AN and HY do not automatically qualify them for authorship. In the section “Authors’ contributions”, please provide further clarifications on their contributions, and see our guidelines for authorship below.

Thank you for your comment. According to your suggestion, we provide further clarifications on the authors’ contributions (Page 26, Line 384).

5. Funding

-- In the section 'Funding', please also describe the role of the funding body/bodies in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Thank you for your comment. According to your suggestion, we described the role of the funding in the section of ‘Funding’ (Page 25, Line 378).
6. Availability of Data and Materials

-- Please remove the provided email address and state the 'corresponding author'.

Thank you for your comment. According to your suggestion, we removed e-mail address and stated the corresponding author in the section of ‘Availability of Data and Materials’ (Page 25, Line 371).

7. Response

-- Thank you for providing a response to the reviewers. As this document is no longer required at this stage of the publication process, please remove it from your submission’s supplementary files.

Thank you for your comment. According to your suggestion, we removed response letter to the reviewers from the revised submissions.

8. Formatting

-- Please ensure that all figures/tables and supplementary files are cited within the text. Any items which are not cited may be deleted by our production department upon publication.

Thank you for your comment. According to your suggestion, we have checked and confirmed that all figures, tables and supplementary files were cited within the text.